Hematologia Geral

Estudo randomizado | Carboximaltose férrica IV vs. fumarato ferroso por via oral em crianças anêmicas com doença inflamatória intestinal

31 Jan, 2023 | 11:51h

Ferric carboxymaltose versus ferrous fumarate in anemic children with inflammatory bowel disease: the POPEYE randomized controlled clinical trial – The Journal of Pediatrics

 

---

Diretrizes ESMO | Tromboembolismo venoso em pacientes com câncer

16 Jan, 2023 | 10:59h

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology

Conteúdo relacionado: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

Infográfico: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

 

---

Diretriz | Manejo periprocedimento de agentes antitrombóticos e trombocitopenia para procedimentos comuns em oncologia.

17 Out, 2022 | 13:31h

Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH – Journal of Thrombosis & Haemostasis

 

---

Diretriz | Avaliação e tratamento do tromboembolismo venoso.

17 Out, 2022 | 13:05h

Joint Guideline on Venous Thromboembolism – 2022 – Arquivos Brasileiros de Cardiologia

 

---

Revisão sistemática | Estabilizadores de HIF (Hypoxia‐Inducible Factor) para a anemia na doença renal crônica.

12 Set, 2022 | 11:25h

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library

Resumo: Are hypoxia-inducible factor stabilisers effective for management of anaemia among people with chronic kidney disease? – Cochrane Library

 

---

Seguimento de 48 semanas de um estudo randomizado | Pegcetacoplan vs. eculizumabe em pacientes com hemoglobinúria paroxística noturna.

12 Set, 2022 | 11:16h

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Estudo original: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

 

Comentário no Twitter (fio – clique para saber mais)

NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X

— The Lancet Haematology (@TheLancetHaem) September 1, 2022

 

---

Opinião | Ácido tranexâmico para uma cirurgia mais segura: o momento é agora.

8 Set, 2022 | 14:21h

Tranexamic acid for safer surgery: the time is now – British Journal of Surgery

Conteúdos relacionados:

#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.

Update on applications and limitations of perioperative tranexamic acid.

RCT | Effect of high- vs. low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery.

Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients – this large observational study did not show an increased risk for venous thromboembolism, myocardial infarction, seizures, ischemic strokes, or transient ischemic attacks, irrespective of patient high-risk status at baseline

M-A: Intravenous tranexamic acid in surgical patients is not associated with increased risk of thromboembolic events and mortality

 

---

Breve revisão | Tromboprofilaxia na terapia intensiva.

8 Set, 2022 | 14:06h

Thromboprophylaxis in critical care – Intensive Care Medicine

 

---

Revisão | Uso de transfusão de sangue total no trauma.

8 Set, 2022 | 13:34h

The Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports

 

---

Revisão sistemática | Hidroxiureia para doença falciforme.

6 Set, 2022 | 12:42h

Hydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library

Resumo: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library

 

---